Market Cap 16.84M
Revenue (ttm) 0.00
Net Income (ttm) -44.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,765,327
Avg Vol 14,877,256
Day's Range N/A - N/A
Shares Out 46.08M
Stochastic %K 31%
Beta 0.52
Analysts Sell
Price Target $4.00

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology
Sector: Healthcare
Phone: 608 441 8120
Address:
100 Campus Drive, Florham Park, United States
EvenBetter99
EvenBetter99 Dec. 4 at 10:16 PM
$CLRB solid
0 · Reply
Zergg
Zergg Dec. 4 at 1:42 AM
$CLRB Christmas Catalyst? 🎄🥹
0 · Reply
higgggghhhher
higgggghhhher Dec. 3 at 6:30 PM
$CLRB https: https://www.cellectar.com/our-science New website
2 · Reply
Sposas
Sposas Dec. 3 at 3:51 PM
0 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:46 PM
$CLRB @higgggghhhher pt. 4 Let me help people here say your new year wishes out loud: "I want to break even," to put it politely like all investors here. Impolitely, you are all losers and bagholders, and now, unfortunately, part of a criminal ring. Oh, by the way, you are teaming up with losers such as "zergg," who does not even understand where the additional 1 million outstanding shares came from. Good luck recouping your 99% loss.
2 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:45 PM
$CLRB @higgggghhhher pt. 3 Do you see the pattern here? If not, take a look at your account, which is down 99%. When this stock was still trading around $6, I said here that it would hit an all-time low soon, below $4, and it made it to under $3 in no time. I can assure you that another dilution—not a warrant, but an outright equity sale—is underway. All investors here will be diluted by another 50%, if not more. The tactic is to extend operations and be prepared for another reverse split if necessary, as the current outstanding shares are not feasible for such.
0 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:45 PM
$CLRB @higgggghhhher pt. 2 This is the exact tactic the management uses. The management always speaks of how positive things are, but then in the actual legally binding documents, they state things cautiously. For example, consider this statement: "Last month, Cellectar announced that the FDA also granted RPDD for CLR 131 for the treatment of neuroblastoma. If CLR 131 is approved by the FDA for either neuroblastoma or rhabdomyosarcoma, the rare pediatric disease designation may enable Cellectar to receive a priority review voucher. Priority review vouchers can be used by the sponsor to receive priority review for a future NDA or BLA submission, which would reduce the FDA review time from 12 months to six months. Currently, these vouchers can also be transferred or sold to another entity. Over the last 16 months, five priority review vouchers were sold for between $110 million to $150 million each."
0 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:44 PM
$CLRB @higgggghhhher pt. 1 I cannot believe that after all these 99% wipeouts, including the 90% wipeout in 2025 alone, you have become a part of the mafia's misleading information (read again, not misinformation). For instance, the information you provided will make a novice believe that the company has priority review vouchers, which could be sold for between $110 million to $150 million each and used for operational funding. Newbies could be misled into believing that a Rare Pediatric Disease Designation is the same as a priority review voucher, get high, jump on this robbery train, and then get a 90% haircut.
0 · Reply
Cookem_up09
Cookem_up09 Dec. 3 at 2:20 PM
$CLRB should be around $4-$6
0 · Reply
Zergg
Zergg Dec. 3 at 12:33 AM
$CLRB come on baby come onnnn
0 · Reply
Latest News on CLRB
Cellectar Announces Plan to Explore Strategic Alternatives

Apr 30, 2025, 8:05 AM EDT - 7 months ago

Cellectar Announces Plan to Explore Strategic Alternatives


Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 12:41 PM EDT - 9 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript


EvenBetter99
EvenBetter99 Dec. 4 at 10:16 PM
$CLRB solid
0 · Reply
Zergg
Zergg Dec. 4 at 1:42 AM
$CLRB Christmas Catalyst? 🎄🥹
0 · Reply
higgggghhhher
higgggghhhher Dec. 3 at 6:30 PM
$CLRB https: https://www.cellectar.com/our-science New website
2 · Reply
Sposas
Sposas Dec. 3 at 3:51 PM
0 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:46 PM
$CLRB @higgggghhhher pt. 4 Let me help people here say your new year wishes out loud: "I want to break even," to put it politely like all investors here. Impolitely, you are all losers and bagholders, and now, unfortunately, part of a criminal ring. Oh, by the way, you are teaming up with losers such as "zergg," who does not even understand where the additional 1 million outstanding shares came from. Good luck recouping your 99% loss.
2 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:45 PM
$CLRB @higgggghhhher pt. 3 Do you see the pattern here? If not, take a look at your account, which is down 99%. When this stock was still trading around $6, I said here that it would hit an all-time low soon, below $4, and it made it to under $3 in no time. I can assure you that another dilution—not a warrant, but an outright equity sale—is underway. All investors here will be diluted by another 50%, if not more. The tactic is to extend operations and be prepared for another reverse split if necessary, as the current outstanding shares are not feasible for such.
0 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:45 PM
$CLRB @higgggghhhher pt. 2 This is the exact tactic the management uses. The management always speaks of how positive things are, but then in the actual legally binding documents, they state things cautiously. For example, consider this statement: "Last month, Cellectar announced that the FDA also granted RPDD for CLR 131 for the treatment of neuroblastoma. If CLR 131 is approved by the FDA for either neuroblastoma or rhabdomyosarcoma, the rare pediatric disease designation may enable Cellectar to receive a priority review voucher. Priority review vouchers can be used by the sponsor to receive priority review for a future NDA or BLA submission, which would reduce the FDA review time from 12 months to six months. Currently, these vouchers can also be transferred or sold to another entity. Over the last 16 months, five priority review vouchers were sold for between $110 million to $150 million each."
0 · Reply
szcyxzh
szcyxzh Dec. 3 at 2:44 PM
$CLRB @higgggghhhher pt. 1 I cannot believe that after all these 99% wipeouts, including the 90% wipeout in 2025 alone, you have become a part of the mafia's misleading information (read again, not misinformation). For instance, the information you provided will make a novice believe that the company has priority review vouchers, which could be sold for between $110 million to $150 million each and used for operational funding. Newbies could be misled into believing that a Rare Pediatric Disease Designation is the same as a priority review voucher, get high, jump on this robbery train, and then get a 90% haircut.
0 · Reply
Cookem_up09
Cookem_up09 Dec. 3 at 2:20 PM
$CLRB should be around $4-$6
0 · Reply
Zergg
Zergg Dec. 3 at 12:33 AM
$CLRB come on baby come onnnn
0 · Reply
higgggghhhher
higgggghhhher Dec. 2 at 9:59 PM
$CLRB Huge. https://www.yahoo.com/news/articles/house-passes-bill-reauthorises-fda-163213828.html
0 · Reply
EvenBetter99
EvenBetter99 Dec. 2 at 5:46 PM
$CLRB USD 100k per treatment multiply with 1000 patients = USD 100 M revenue. Market Cap 20* 100 M = USD 2 B. 🚀🚀🚀🚀🚀 Iopofosine for WaM would help patients and shows efficiency of their PDC Techn for other treatments in pipeline.
0 · Reply
Siuolman58
Siuolman58 Dec. 2 at 12:30 PM
$CLRB Cleared to 4.03 and then 4.98
0 · Reply
Zergg
Zergg Dec. 2 at 2:32 AM
$CLRB this is getting interesting
0 · Reply
Siuolman58
Siuolman58 Dec. 1 at 6:46 PM
$CLRB Seems as tho there are not many sellers. Cleared the resistance and now has a clear path up!
0 · Reply
revuelto
revuelto Dec. 1 at 6:13 PM
$CLRB massively undervalued… this is going to be one of those “should’ve grabbed the dip with both hands” moments in hindsight 😀
0 · Reply
EvenBetter99
EvenBetter99 Nov. 29 at 10:53 AM
$CLRB only their PDC tech for WaM as a second line therapy is worth billions. 🚀🚀🚀🚀
0 · Reply
Zergg
Zergg Nov. 28 at 8:42 PM
$CLRB short interest at around 4% down 50%
1 · Reply
Zergg
Zergg Nov. 28 at 8:40 PM
$CLRB 84% retail ownership here, 7.4% institutional, 4.5% insiders
0 · Reply
Siuolman58
Siuolman58 Nov. 28 at 5:54 PM
$CLRB Someone knows!!!
1 · Reply
JTSawyer66
JTSawyer66 Nov. 28 at 5:34 PM
0 · Reply
Zergg
Zergg Nov. 27 at 3:45 PM
$CLRB for a company to maintain this long, pre-revenue, developing cancer drugs and having to dilute and r/s to function for an extended period of time, CLRB appears to have operated very well given the circumstances. 4 million share float at give or take around a 3$ share price. A lot of companies would have been delisted or crumbled by this point in their journey, yet they’ve managed to get where they are now, NASDAQ compliant with an ultra low float and cash runway into Q3 2026 with many potential catalysts on the horizon. Then you look at the clinical data and realize why they made it this far, these drugs could be revolutionary in the oncology sector. Extremely effective at specifically targeting/destroying cancer cells and significantly reduced toxicity to the patient.
0 · Reply